Chris Shibutani analyst GOLDMAN SACHS

Currently out of the existing stock ratings of Chris Shibutani, 62 are a BUY (56.36%), 42 are a HOLD (38.18%), 6 are a SELL (5.45%).

Chris Shibutani

Work Performance Price Targets & Ratings Chart

Analyst Chris Shibutani works at GOLDMAN SACHS with a stock forecast success ratio of 47.95% fulfilled within 116.76 days on average. Previously, Chris Shibutani worked at TD COWEN.

Chris Shibutani’s has documented 213 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RPRX, Royalty Pharma Plc at 20-Feb-2024.

Wall Street Analyst Chris Shibutani

Analyst best performing recommendations are on TRDA (ENTRADA THERAPEUTICS).
The best stock recommendation documented was for TRDA (ENTRADA THERAPEUTICS) at 11/23/2021. The price target of $29 was fulfilled within 6 days with a profit of $4.87 (20.18%) receiving and performance score of 33.64.

Average potential price target upside

ALKS Alkermes Plc BNTX BioNTech SE JNJ Johnson & Johnson MCRB Seres Therapeutics NBIX Neurocrine Biosciences NKTR Nektar Therapeutics PBYI Puma Biotechnology RVMD Revolution Medicines TNGX Tango Therapeutics UTHR United Therapeutics ABBV AbbVie BMY Bristol-Myers Squibb Company LLY Eli Lilly and Company PFE Pfizer AMLX Amylyx Pharmaceuticals EXAI Exscientia Ltd ADR TRDA Entrada Therapeutics EQRX EQRx RPRX Royalty Pharma Plc KYMR Kymera Therapeutics INVA Innoviva RXDX Prometheus Biosciences ERAS Erasca MDCO The Medicines Company RPTX Repare Therapeutics RVNC Revance The SDGR Schrodinger SNDX Syndax Pharmaceuticals OGN Organon

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

39

$10.09 (34.90%)

35

8 days ago

4/7 (57.14%)

$6.44 (19.78%)

164

Hold

29

$0.09 (0.31%)

27

1 months 22 days ago

8/10 (80%)

$1.26 (4.54%)

125

Hold

33

$4.09 (14.15%)

33

3 months 4 days ago

2/4 (50%)

$8.82 (36.48%)

107

Buy

35

$6.09 (21.07%)

36

3 months 29 days ago

0/5 (0%)

$12.04 (52.44%)

Buy

50

4 months ago

2/3 (66.67%)

$7.95 (18.91%)

620

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Chris Shibutani is most bullish on?

Potential upside of $21.46 has been obtained for AMLX (AMYLYX PHARMACEUTICALS)

Which stock is Chris Shibutani is most reserved on?

Potential downside of -$12.03 has been obtained for UTHR (UNITED THERAPEUTICS)

What Year was the first public recommendation made by Chris Shibutani?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?